Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon™ PTH in Adult Hypoparathyroidism
– Six-month data from PaTH Forward open-label extension support potential use of TransCon PTH as a hormone replacement therapy for adult […]